Results 41 to 50 of about 25,024 (199)
Idiosyncratic drug-induced neutropenia & agranulocytosis.
, 2017 International audienceFew data is currently available on neutropenia and agranulocytosis related to drug intake. We report here data on 203 patients with established idiosyncratic drug-induced agranulocytosis, followed up in a referral centre within a ...
Korganow, Anne-Sophie +13 more
core +1 more source
Case Reports in Medicine, 2016 Background. Chlorpromazine and trimethoprim-sulfamethoxazole (TMP/SMX) are two commonly prescribed medications by physicians. Either of those medications could cause fatal drug-induced agranulocytosis, with an unclear underlying mechanism. The likelihood
Anil Jha, Hassan Ghoz, Nicholas James
doaj +1 more source
Rheumatology &Autoimmunity, EarlyView.A proposed mechanistic framework of systemic lupus erythematosus (SLE) and autoimmune thyroid disease (AITD) pathogenesis. In Stage 1, genetically susceptible individuals harbor risk variants within major histocompatibility complex (HLA) and non‐HLA loci that impair central and peripheral immune tolerance mechanisms within the thymic and peripheral ...
Elisa Elisa +3 more
wiley +1 more source
Antithyroid drug-induced agranulocytosis [PDF]
, 1999 Thyrotoxicosis is a common endocrine disorder. Antithyroid drug therapy is the standard treatment for this disease, especially in young women of reproductive age. A serious side effect of antithyroid drug use, however, is agranulocytosis.
Liang, RHS, Lee, CH
core
An investigation into clozapine induced agranulocytosis [PDF]
, 1996 Adverse haematological reactions to drugs can prove serious if undetected. The response can be related to dose and time but affected, cells usually return to normal when treatment is withdrawn.
Wilkes, Susanna Jane Lawson
core +1 more source
Case Reports in Medicine, 2018 When elderly patients are prescribed many different medications, the risk for developing serious adverse events should be kept in mind. One of these adverse events is agranulocytosis, which, although rare, can be life-threatening if left untreated.
Yohei Kubota, Toh Yoon Ezekiel Wong
doaj +1 more source
Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis: A Review for Clinical Practice
Clinical Endocrinology, EarlyView.ABSTRACT Objective Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging.
Lorenzo Scappaticcio +7 more
wiley +1 more source
Clinical Case Reports, 2018 Key Clinical Message Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment.
Hyunsam Kim, Jeongmin Lee, Jeonghoon Ha
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang +3 more
wiley +1 more source
Agranulocytosis: a rare complication of the thionamides
, 2023 Agranulocytosis is a rare and life-threatening side effect of antithyroid drugs (ATD); it has been reported in
Hawa Juma El-Shareif
core +1 more source